To provide a systematic evaluation of the diverse therapeutic mechanisms mediated by COF-based nanoplatforms, Table 1 summarizes the morphologies, particle sizes, and underlying action mechanisms of representative COF systems
As a specific ASIC1a blocker, Psalmotoxin 1 (PcTX1) injected in the ventricular could reduce the focal infarct size up to 60% forever or temporarily in the cerebral ischemia model (Xiong et al., 2004)
Specifications Composition (per vial): KPV 10 mg BPC-157 10 mg TB-500 10 mg GHK-Cu 50 mg (Total actives: 80 mg) Appearance: Lyophilized powder (hue may range blue-green due to copper complex) Purity: 99% (each component), HPLC/MS verified Manufacturing: GMP-compliant facility, USA Packaging: Sterile, research-grade vial Storage: 20 C, desiccated
While a trend toward increased survival probability was observed in animals treated with either compound or their combination, the effect was not statistically significant ( Figure 9B )